0001061983-21-000247.txt : 20211102 0001061983-21-000247.hdr.sgml : 20211102 20211102171643 ACCESSION NUMBER: 0001061983-21-000247 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211101 FILED AS OF DATE: 20211102 DATE AS OF CHANGE: 20211102 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cragg David CENTRAL INDEX KEY: 0001316459 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50633 FILM NUMBER: 211372522 MAIL ADDRESS: STREET 1: 280 EAST GRAND AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CYTOKINETICS INC CENTRAL INDEX KEY: 0001061983 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943291317 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 280 EAST GRAND AVENUE STREET 2: . CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (650) 624-3000 MAIL ADDRESS: STREET 1: 280 EAST GRAND AVENUE CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 edgardoc.xml PRIMARY DOCUMENT X0306 4 2021-11-01 0 0001061983 CYTOKINETICS INC CYTK 0001316459 Cragg David 280 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 0 1 0 0 Chief HR & Admin Officer Common Stock 2021-11-01 4 M 0 6675 6.0 A 145379 D Common Stock 2021-11-01 4 S 0 6675 34.8896 D 138704 D Common Stock 2021-11-01 4 M 0 18325 6.0 A 157029 D Common Stock 2021-11-01 4 S 0 18325 34.8896 D 138704 D Incentive Stock Option (right to buy) 6.0 2021-11-01 4 M 0 18325 0.0 D 2013-04-05 2023-03-05 Common Stock 18325 0 D Non-Qualified Stock Option (right to buy) 6.0 2021-11-01 4 M 0 6675 0.0 D 2013-04-05 2023-03-05 Common Stock 6675 0 D Amount of securities beneficially owned following reported transaction has been adjusted by 1,541 shares purchased pursuant to ESPP but were not previously reported. Reporting persons Form 4 filed on 10/1/2021 erroneously stated that the reported 137,123 shares owned following reporting persons transaction on October 1, 2021 included 13,678 shares of common stock purchased pursuant to ESPP, but in fact only 12,137 shares of common stock purchased pursuant to ESPP were included in that 137,123 share total. Transaction effected pursuant to a 10b5-1 plan meeting the requirements of Rule 10b5-1(c) under the Exchange Act entered into by the Reporting Person on March 31, 2021. Includes up to 13,678 shares of common stock purchased pursuant to the Cytokinetics, Incorporated Employee Stock Purchase Plan. By: Robert Wong For: David Cragg 2021-11-02